Company Overview of ALPHAEON Corporation
ALPHAEON Corporation provides beauty, wellness, and lifestyle products in the United States. It offers age defense creams for dry, normal, and combination skin; and revitalizing concentrate serums, face and eyes cleansing solutions, skin radiance smoothing creams, and deep repair soothing balms. The company offers skin care assessment solutions; credit cards that provide financing options for individuals; and PRN (Physician Recommended Nutriceuticals) products, which include omega-3 EPA and vitamin D3 soft-gels; omega-3 EPA and vitamin D3 liquids; macular vitamins; and custom-formulated omega-3 EPA, vitamin D3, and carotenoids soft-gels for dry eyes. It also helps patients to find physicians...
18191 Von Karman Avenue
Irvine, CA 92612
Founded in 2012
Key Executives for ALPHAEON Corporation
Chief Executive Officer and Director
President and Chief Operating Officer
President of Asia Pacific
Compensation as of Fiscal Year 2015.
ALPHAEON Corporation Key Developments
ALPHAEON Corporation Unveils TouchMD® Platform
May 15 15
ALPHAEON Corporation announced they are unveiling the new TouchMD® platform at the annual American Society of Aesthetic Plastic Surgeons meeting in Montreal. TouchMD version 4 brings a full redesign of the patient consultation platform, with an enhanced visual experience through new layouts that showcase practice content and maximize screen space, intuitive navigation allowing for quick access to all images and content, built-in advanced drawing tools, and the ability to brand and customize the platform for each practice. Version 4 also includes a modern redesign of myTouchMD, the consumer portal.
ALPHAEON Corporation Appoints Jeff Castillo as President of the Americas, and Kuntal Joshi as President of Asia Pacific
Jan 28 15
ALPHAEON Corporation announced that Jeff Castillo has joined the organization as President of the Americas, and Kuntal Joshi has joined as President of Asia Pacific. Mr. Castillo and Mr. Joshi each bring more than 25 years of experience in the medical device sector to their roles at the company. Mr. Castillo was most recently a Divisional Vice President at Abbott Medical Optics (AMO) where he focused on leading the Americas organization to double-digit growth through greater alignment and focus on customer needs and market dynamics. While at AMO, Jeff was responsible for deploying a customer focused strategy concentrating on strengthening AMO's value proposition through the creation of new services, launching value added products, and maximizing the portfolio. Prior to AMO, Mr. Castillo spent 22 years at Johnson & Johnson, where he held a variety of senior commercial positions based in the U.S. and Latin America. Prior to joining ALPHAEON, Mr. Joshi spent the last 12 years in the Asia Pacific Region.
FDA Accepts Investigational New Drug Application for ALPHAEON's Neurotoxin EVOSYAL
Sep 4 14
ALPHAEON(R) Corporation, subsidiary of Strathspey Crown Holdings LLC, announced that the U.S. Food and Drug Administration (FDA) accepted the Investigational New Drug (IND) application to conduct clinical studies for EVOSYAL(TM), an advanced Botulinum toxin Type A neurotoxin that was acquired by ALPHAEON last October, as part of the acquisition of Evolus Inc. According to the ASPS(R), Botulinum toxin Type A was injected for cosmetic purposes more than 6 million times last year, accounting for over 2 billion dollars of consumer spend annually, which was a 3% increase from the previous year. ALPHAEON expects the initial clinical trial to be fully enrolled by the end of 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions